Discontinue use in occurrence of early symptoms & signs of hypersensitivity reaction, including hives, generalized urticaria, chest tightness, dyspnea, wheezing, faintness, hypotension, & anaphylaxis. Thromboembolic events (higher incidence in females); VWD patients of high thrombotic risk receiving coagulation factor replacement therapy. Made from pooled human plasma; may carry a risk of transmitting infectious agents, eg, viruses & Creutzfeldt-Jakob disease agent. Potential formation of factor VIII inhibitors; carefully monitor bleeding in patients w/ factor VIII inhibitors. Pregnancy.